GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MEM-288 overview

MEM-288 is under development for the treatment of solid tumors including non-small cell lung cancer, cutaneous squamous cell carcinoma, Merkel cell carcinoma, melanoma pancreatic cancer, triple negative breast cancer and head and neck cancer. It is administered through intratumor route. The drug candidate is an oncolytic virus expressing CD40 ligand (CD40L) and interferon-beta (IFN-beta). It acts by targeting cells expressing CD40.

Memgen overview

Memgen LLC (Memgen) is a biotechnology company that discovers, designs and develops viral immunotherapies for the treatment of lung, breast, pancreatic, and prostate cancers. Memgen is headquartered in Houston, Texas, the US.

For a complete picture of MEM-288’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.